// App-Quantinova.ai

3098 : Ruxolitinib Reduces Endothelial Pro-Adhesive Interactions: Implications for JAK2V617+ MPN Thrombosis

Researchers

Presenter

  • Angelica DaSilva

Principal Investigators

  • Elena Aronovich

  • Aithanh Nguyen

  • Julia Nguyen

  • David Reynolds

  • Geneva D. Doak

  • Gregory M. Vercellotti

  • David K. Wood

  • Joan D. Beckman

Medical Centers

  • University of Minnesota, Minneapolis, MN

  • Division of Hematology Oncology and Transplantation, University of Minnesota, Minneapolis, MN

  • Vascular Biology Center, Division of Hematology, Oncology & Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN

  • Department of Mechanical Engineering, Iowa State University, Ames, IA

  • Biomedical Engineering, University of Minnesota, Minneapolis, MN

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Venous thrombosis

Biomarkers

  • Vascular cell adhesion molecule 1

  • von Willebrand factor

Drug/Treatment

  • Ruxolitinib phosphate

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved